Novo Nordisk to Cut Prices of Insulin Products by Over 70%

MT Newswires Live

Dec 06, 2024

Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.

The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.

Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.

Price: 108.87, Change: -0.10, Percent Change: -0.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2489449634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489449634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489449634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 02:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489449634","market":"nz","top_or_hot":-1,"title":"Novo Nordisk to Cut Prices of Insulin Products by Over 70%","media":"MT Newswires Live","content":"<html><body><p> Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.</p><p>The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.</p><p>Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.</p><p>Price: 108.87, Change: -0.10, Percent Change: -0.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk to Cut Prices of Insulin Products by Over 70%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk to Cut Prices of Insulin Products by Over 70%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-06 02:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.</p><p>The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.</p><p>Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.</p><p>Price: 108.87, Change: -0.10, Percent Change: -0.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489449634","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489449634","pubTimestamp":1733423321,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.Price: 108.87, Change: -0.10, Percent Change: -0.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVO":"诺和诺德","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO.AU":"NOVO RESOURCES CORP-CDI","BK7104":"黄金","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"诺和诺德将胰岛素产品降价超70%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"NVO.AU":1},"content_text":"Novo Nordisk (NVO) Thursday said it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026.The price of vials and pre-filled injector pens of the company's fast-acting Fiasp insulin will drop 75%, matching the price of its Novolog insulin, while the price of various dispensers of its long-acting Tresiba insulin analog will fall by 72.2%, making it 20% lower than its unbranded equivalent, insulin degludec, the Danish drugmaker said.Novo Nordisk will cease production of its unbranded insulin biologicals by the end of 2025 and said it wanted to provide healthcare professionals, wholesalers and insurers with more than 12 months advance notice to ensure a smooth transition for patients.Price: 108.87, Change: -0.10, Percent Change: -0.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}